Sign in to continue:

Friday, April 3rd, 2026

Franklin Covey Reports Q2 2026 Results: Revenue Flat, Adjusted EBITDA Up 99%, Reaffirms Fiscal 2026 Guidance





Franklin Covey Reports Q2 Fiscal 2026 Results: Details & Shareholder Insights

Franklin Covey Reports Second Quarter Fiscal 2026 Results: Key Developments and Shareholder Implications

Summary of Key Results

  • Q2 FY2026 Revenue: \$59.6 million (flat year-over-year)
  • Enterprise North America Invoiced Amounts: Up 7% for the second consecutive quarter
  • Deferred Revenue: Up 7% year-over-year to \$101.5 million
  • Net Loss: \$(2.0) million, or \$(0.17) per share, compared with \$(1.1) million, or \$(0.08) per share, in Q2 FY2025
  • Adjusted EBITDA: Up 99% to \$4.1 million (from \$2.1 million in Q2 FY2025)
  • Liquidity: Over \$76 million, including \$13.7 million cash and a fully available \$62.5 million credit facility
  • Share Repurchases: \$17.0 million spent to repurchase ~947,000 shares during the quarter
  • Company Guidance: Fiscal 2026 revenue guidance of \$265–\$275 million and Adjusted EBITDA of \$28–\$33 million reaffirmed

Detailed Financial Performance

Segment Performance

  • Enterprise Division: Revenue down to \$41.6 million from \$43.6 million a year earlier, driven by a \$2.0 million decline in North America, partially offset by a small increase internationally. Notably, North America invoiced amount grew by 7% for the second straight quarter. Deferred revenue for this division increased 15% year-over-year.
  • Education Division: Revenue rose by \$2.4 million (16%) to \$17.5 million, driven by increased training, coaching, materials, and subscription revenue.
  • Subscription and Subscription Services: Q2 revenue reached \$50.9 million (vs. \$49.5 million prior year). Invoiced subscription and contractually committed services grew 16% to \$39.3 million.

Profitability and Cash Flow

  • Net Loss: \$(2.0) million, widened from \$(1.1) million in Q2 FY2025.
  • Adjusted EBITDA: Nearly doubled to \$4.1 million, reflecting operational improvements and cost controls.
  • Operating Cash Flow: \$16.3 million for Q2 FY2026 (vs. \$(1.4) million used in Q2 FY2025).
  • Free Cash Flow: \$13.2 million, a strong recovery from \$(3.6) million in the prior year.
  • Cash and Cash Equivalents: \$13.7 million (down from \$40.4 million a year ago), though overall liquidity remains robust due to the unused credit facility.

Shareholder Actions and Capital Allocation

  • Share Repurchases: The company repurchased approximately 947,000 shares (\$17.0 million worth) during the quarter, including 922,000 shares via open market transactions under Rule 10b5-1 plans. An additional 25,000 shares were withheld to cover statutory taxes on vested stock-based awards.
  • Deferred Revenue & Contract Lengths: At quarter-end, 59% of North American AAP contracts were for at least two years (up from 55% last year), and 62% of contracted values were multi-year in duration.
  • Unbilled Deferred Revenue: \$64.9 million, steady year-over-year.

Outlook and Guidance

  • Full-Year Fiscal 2026 Guidance: Revenue of \$265–\$275 million and Adjusted EBITDA of \$28–\$33 million (in constant currency) reaffirmed.
  • Growth Expectations: Management expects renewed growth in both revenue and Adjusted EBITDA in FY2026, with continued strong invoiced growth translating into meaningful reported revenue and EBITDA in FY2027.
  • Strategic Context: The company believes its go-to-market transformation is yielding results, particularly in Enterprise North America. AI adoption is cited as a growth driver, with increased demand for Franklin Covey’s offerings in leadership, trust, change management, and execution.

Leadership Commentary

CEO Paul Walker: “We delivered our second consecutive quarter of 7% invoiced growth in Enterprise North America as strong execution on our go-to-market strategy continues to gain traction. We believe we are at an inflection point where the return on investment from our transformation is becoming evident. This momentum comes as AI is reshaping how work gets done, and we are seeing increased demand for FranklinCovey’s expertise in helping organizations strengthen the human side of execution.”

CFO Jessi Betjemann: “In the second quarter, we translated operational momentum into improved profitability and strong cash generation. Adjusted EBITDA increased to \$4.1 million, operating cash flow was \$16.3 million, and free cash flow improved to \$13.2 million. We also returned \$17.0 million to shareholders through share repurchases, while maintaining \$76 million of liquidity. We are reaffirming our FY2026 guidance.”

Additional Information and Risks

  • Conference Call: The company will host an earnings call on April 1, 2026, for further discussion and Q&A.
  • Forward-Looking Risks: Investors are cautioned regarding risks including macroeconomic conditions, subscription renewals, client demand for services, acceptance of new products (including AAP portal upgrades), and geopolitical factors. These could materially affect future financial performance.
  • Non-GAAP Metrics: The company highlights Adjusted EBITDA and Free Cash Flow as important supplemental measures but notes they are non-GAAP and may differ from similar metrics used by other companies.

Conclusion: Shareholder Implications

The report signals several potentially price-sensitive developments for Franklin Covey shareholders:

  • Strong growth in invoiced amounts, particularly in Enterprise North America, may indicate future revenue acceleration as deferred revenue converts.
  • Significant share repurchases could positively impact EPS and signal management’s confidence in the business.
  • Reaffirmed guidance and commentary around AI-driven demand position the company favorably for near-term growth, though investors should monitor macroeconomic and execution risks.
  • Improved cash generation and liquidity provide flexibility for continued investment or shareholder returns.
  • Net losses persist, but operational improvements and growth in high-value segments could shift sentiment if trends continue.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review all company filings, consult their financial advisor, and consider their own circumstances before making any investment decisions. Past performance is not indicative of future results. All forward-looking statements involve risks and uncertainties.




View FRANKLIN COVEY CO Historical chart here



Concentrix Corporation 8-K Filing Details: Company Information, SEC Registration, and XBRL Data (Feb 24, 2026)

Concentrix Corporation Announces \$600 Million Offering of 6...

Lexeo Therapeutics 2025 Annual Report: Advancing Genetic Medicine for Cardiovascular Diseases

Lexeo Therapeutics, Inc. 2025 Annual Report: Key Highlights ...

   Ad